Regeneron Pharmaceuticals, Inc. (REGN) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Tarrytown, NY, United States. Le PDG actuel est Leonard S. Schleifer.
REGN a date d'introduction en bourse 1991-04-02, 15,158 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $78.5B.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines for serious diseases. The company's marketed portfolio includes EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and several other specialized therapies for infectious, rare, and cancerous conditions. Regeneron maintains extensive collaboration agreements with leading pharmaceutical and biotechnology companies including Sanofi, Bayer, Roche, and AstraZeneca, as well as strategic partnerships with research institutions and government health agencies. Founded in 1988 and headquartered in Tarrytown, New York, the company focuses on high-value therapeutic areas including ophthalmology, immunology, cardiovascular disease, and oncology.
